Quarterly Result: Ipca Laboratories Ltd.
Technical View:
Ipca Laboratories Ltd., has ended at Rs. 599.7, up by 7.2 points or 1.22% from its earlier closing of Rs. 592.5 on the BSE.
The scrip touched a high and low of Rs. 618 and Rs. 583.8 respectively, after opening at 585.9. Altogether 666552(NSE+BSE) shares have been traded on the counter; and the stock is trading below its 50 DMA.
Standalone Results Q2FY17:
IPCA Laboratories Ltd’s Q2FY17 numbers have come in as a mixed bag in comparison to Bloomberg estimates. Revenue has come in 3.5% greater than the estimate of Rs 855 cr. EBITDA margin is greater by 361 bps from the estimate of 11%. Net profit has been reported 28% lesser than the estimated figure of Rs 76 cr.
The quarter's revenue has soared 17.4% yoy to Rs 885 cr.
Ipca's reported EBITDA has climbed 52.3% yoy to Rs 128 cr while EBITDA margins have improved by 331 bps yoy to 14%. This was supported by operational efficiency.
The company's net profit has upsurged 345% yoy to Rs 54.95 cr, majorly owing to foreign exchange gain of Rs 7.81 compared to loss of Rs 23.63 cr in Q2FY16.